NCT03076437 2021-03-19
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Institute for Innovation and Translational Medicine
Phase 1/2 Completed
Clinical Trials
1 trialsCompleted × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Pharmaceutical Preparations × Clear all